

University of Groningen

## Exploring new ways of measuring the economic value of vaccination with an application to the prevention of rotaviral disease

Standaert, Baudouin Arnould Claire Ghislain Marie

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2015

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Standaert, B. A. C. G. M. (2015). *Exploring new ways of measuring the economic value of vaccination with an application to the prevention of rotaviral disease*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## CURRICULUM VITAE

Baudouin ACGM Standaert (1955) was born in Bruges, Belgium. He first studied medicine (MD) at the KU Leuven, Belgium, and finished the special course in Tropical Medicine at the Instituut voor Tropische Geneeskunde (ITG) in Antwerp, Belgium, in 1982. After his medical degree he immediately went abroad to Suriname with a 1-year scholarship studying the epidemiology of schistosomiasis and the evaluation of road accidents in the city of Paramaribo under the guidance of Prof Dr *BJF Oostburg*. After that year he came back to join the department of Social Medicine and Epidemiology at the University of Antwerp (UIA), under the supervision of Prof Dr *W Eylenbosch*. He started there the research on prostate cancer screening using the PSA-test and the ultrasonography of the prostate gland in collaboration with Prof Dr *L Denis* from the Vrije Universiteit Brussel (VUB). After 3 years he was selected to work in Burundi for initiating the evaluation of the AIDS problem for the AGCD, the Belgian Administration for Cooperation and Development, in an emergency program under the guidance of Prof Dr *P Piot* (ITG, Antwerp). After 2 years in Africa, he was offered a position at the WHO in Geneva to work on cluster analysis of AIDS transmission through infected needles in developing countries. He came back in Belgium in 1987 in the department of Disaster Epidemiology of Prof Dr *M Lechat* at the Université Catholique de Louvain (UCL) in Brussels. The project initiated there was about identifying emergency medical support after cyclone impact in the Solomon Islands in the Pacific Ocean. The project was sponsored by the European Commission. After one year, the decision was taken to move to a next level of career development. He became the new director of the Provincial Institute of Hygiene (PIH) in Antwerp in 1988, working in close collaboration with the provincial deputy politically responsible for that Institute, *J Geuens*. The PIH has a long tradition in working on quality control of water and soil as well as on public health issues in the province. The Institute has around 160 employees split into a lab environment and field work in collecting basic health and environmental information for the province. Many new projects were initiated during that period in developing the institute at the right level of regional, national, and international recognition through new collaborations with universities and other institutes in Belgium and in Europe including Prof Dr *L Denis* (prostate disease), Prof Dr *P Boyle* (cancer prevention at the International Agency on Research of Cancer (IARC)), and Prof Dr *M Lechat* (registry of EUROCAT in the province of Antwerp), and Prof Dr *M Barch* of the Provincial Institute of Liège (Healthy Cities). During that period B Standaert became the representative of Belgium in the scientific board of IARC in Lyon, France. After a few years the interest for economic evaluations in health care emerged with the collaboration of *K Torfs* from the University of Antwerp (UFSIA). Health economics was at that time a new domain to explore with a clear necessity to value new medical products coming into the health care market. Because B Standaert was still working on prostate diseases pharmaceutical companies were interested in getting his expertise in house. A new critical decision had to be taken in 1995 to move to the industry and to stop working for the public health institute. He took that decision in May 1995 to join AMGEN to become

the first health economist for that biotech company in Europe. Over the years a small health economic team was set up in Brussels with 8 people coordinating all the health economic activities in Europe for AMGEN but reporting directly to the health economic team in the US under the leadership of Dr *H Erder*. Then the decision was taken by upper management of AMGEN to move the European HE-program from Brussels to Zug in Switzerland in 2005 where the commercial head-quarters for the company in Europe were located. That was the reason for B Standaert to decide to move to another international group in Belgium and to start working on vaccines. In November 2005, B Standaert became the head of the global health economic group of vaccines in GSK Bio, Rixensart, Belgium. He started with a small team of 3 collaborators 9 years ago, first working on the health economic assessment of Rotarix and Cervarix and then later on that of Synflorix. The group of Health Economics (HE) counts today 18 people and the team works closely with the clinical and the commercial groups of GSK Vaccines worldwide. The overall HE program is supervised by Dr *T Breuer*, head of the Vaccine Value and Human Science program within Research and Development of GSK Vaccines. The HE-team has a wide experience in developing different types of economic assessment tools going from the very simple back-of-the-envelope models to the more advanced dynamic and macro-economic models for pandemic infectious diseases such as malaria, TB, HIV, Flu. The health economic group also explores new economic evidence away from the conventional cost-effectiveness analysis such as optimisation modelling, return on investment, and macro-economic evaluations. Collaboration with many international groups and universities in Belgium and in the Netherlands, in particular the University of Groningen, has been set up to exchange ideas, study results and projects. B Standaert has numerous publications in the many different fields he has worked on including prostate diseases, AIDS, cancer, infectious diseases, and public health. He was also during several years the representative of the industry for the working group on economic modelling of the WHO (QUIVERT/IVIR), Geneva, in Switzerland.